J. Goldman & Co LP Buys New Shares in Atyr PHARMA INC (NASDAQ:ATYR)

J. Goldman & Co LP bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 300,131 shares of the company’s stock, valued at approximately $1,086,000. J. Goldman & Co LP owned approximately 0.36% of Atyr PHARMA as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. Group One Trading LLC purchased a new position in Atyr PHARMA during the fourth quarter valued at $26,000. Alterna Wealth Management Inc. purchased a new position in Atyr PHARMA during the fourth quarter valued at $36,000. Victory Capital Management Inc. purchased a new position in Atyr PHARMA during the fourth quarter valued at $37,000. Raymond James Financial Inc. purchased a new position in shares of Atyr PHARMA in the fourth quarter valued at about $39,000. Finally, XTX Topco Ltd purchased a new position in shares of Atyr PHARMA in the fourth quarter valued at about $40,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Atyr PHARMA Stock Performance

NASDAQ ATYR opened at $3.29 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. Atyr PHARMA INC has a 1-year low of $1.42 and a 1-year high of $4.66. The business has a 50 day simple moving average of $3.27 and a two-hundred day simple moving average of $3.40. The stock has a market capitalization of $292.82 million, a PE ratio of -3.50 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. On average, research analysts predict that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ATYR has been the topic of several recent analyst reports. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partners started coverage on shares of Atyr PHARMA in a report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a report on Friday, March 14th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $18.60.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.